Endogenous neurotoxic dopamine derivative covalently binds to Parkinson's disease-associated ubiquitin C-terminal hydrolase L1 and alters its structure and function

Journal of Neurochemistry

Volumn 130, Issue 6, 2014, Pages 826-838

  Contu, Viorica Raluca ^a,c   Kotake, Yaichiro ^a   Toyama, Takashi ^b,d   Okuda, Katsuhiro ^a   Miyara, Masatsugu ^a   Sakamoto, Shuichiro ^a   Samizo, Shigeyoshi ^a   Sanoh, Seigo ^a   Kumagai, Yoshito ^b   Ohta, Shigeru ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

^c UNIVERSITY OF YAMANASHI   (Japan)

^d NATIONAL INSTITUTE OF NEUROSCIENCE   (Japan)

Author keywords

aggregation; covalent modification; endogenous dopamine derivative; UCH L1

Indexed keywords

1 (3',4' DIHYDROXYBENZYL) 1,2,3,4 TETRAHYDROISOQUINOLINE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE DERIVATIVE; HYDROLASE; UBIQUITIN C TERMINAL HYDROLASE L1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; 1-(3',4'-DIHYDROXYBENZYL)-1,2,3,4-TETRAHYDROISOQUINOLINE; CATECHOL; CATECHOL DERIVATIVE; DOPAMINE; DRUG DERIVATIVE; DYES, REAGENTS, INDICATORS, MARKERS AND BUFFERS; NEUROTOXIN; RECOMBINANT PROTEIN; TRETOQUINOL; UBIQUITIN CARBOXYL TERMINAL HYDROLASE L 1, HUMAN; UBIQUITIN CARBOXYL-TERMINAL HYDROLASE L-1, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL SURVIVAL; CELL VIABILITY; CONJUGATION; CONTROLLED STUDY; COVALENT BOND; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IDIOPATHIC DISEASE; IN VITRO STUDY; IN VIVO STUDY; MALE; MESENCEPHALON; MOUSE; NEUROBLASTOMA CELL LINE; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; SURVIVAL RATE; AGAR GEL ELECTROPHORESIS; AGGREGATION; ANIMAL; C57BL MOUSE; CHEMICAL STRUCTURE; CHEMISTRY; COVALENT MODIFICATION; ENDOGENOUS DOPAMINE DERIVATIVE; ESCHERICHIA COLI; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; METABOLISM; TUMOR CELL LINE; UCH-L1; WESTERN BLOTTING;

AGGREGATION; COVALENT MODIFICATION; ENDOGENOUS DOPAMINE DERIVATIVE; UCH-L1;

ANIMALS; BLOTTING, WESTERN; CATECHOLS; CELL LINE, TUMOR; CELL SURVIVAL; DOPAMINE; ELECTROPHORESIS, AGAR GEL; ESCHERICHIA COLI; HUMANS; INDICATORS AND REAGENTS; MESENCEPHALON; MICE; MICE, INBRED C57BL; MODELS, MOLECULAR; NEUROTOXINS; PARKINSON DISEASE; PROTEIN BINDING; RECOMBINANT PROTEINS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION; TRETOQUINOL; UBIQUITIN THIOLESTERASE;

EID: 84908258515     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12762     Document Type: Article

References (48)

1. Abiko Y., and, Kumagai Y., (2013) Interaction of Keap1 modified by 2-tert-butyl-1,4- benzoquinone with GSH: Evidence for S-transarylation. Chem. Res. Toxicol. 26, 1080-1087.
2. Ardley H. C., Scott G. B., Rose S. A., Tan N. G. S., and, Robinson P. A., (2004) UCH-L1 aggresome formation in response to proteasome impairment indicates a role in inclusion formation in Parkinson's disease. J. Neurochem. 90, 379-391.
3. Bilguvar K., Tyagi N. K., Ozkara C., et al,. (2013) Recessive loss of function of the neuronal ubiquitin hydrolase UCHL1 leads to early-onset progressive neurodegeneration. Proc. Natl Acad. Sci. USA 110, 3489-3494.
4. Boudreaux D. A., Maiti T. K., Davies C. W., and, Das C., (2010) Ubiquitin vinyl methyl ester binding orients the misaligned active site of the ubiquitin hydrolase UCHL1 into productive conformation. Proc. Natl Acad. Sci. USA 107, 9117-9122.
5. Cartier A. E., Djakovic S. N., Salehi A., Wilson S. M., Masliah E., and, Patrick G. N., (2009) Regulation of synaptic structure by ubiquitin C-terminal hydrolase L1. J. Neurosci. 29, 7857-7868.
6. Choi J., Levey A. I., Weintraub S. T., Rees H. D., Gearing M., Chin L. S., and, Li L., (2004) Oxidative modifications and down-regulation of ubiquitin carboxyl-terminal hydrolase L1 associated with idiopathic Parkinson's and Alzheimer's diseases. J. Biol. Chem. 279, 13256-13264.
7. Das C., Hoang Q. Q., Kreinbring C. A., Luchansky S. J., Meray R. K., Ray S. S., Lansbury P. T., Ringe D., and, Petsko G. A., (2006) Structural basis for conformational plasticity of the Parkinson's disease-associated ubiquitin hydrolase UCH-L1. Proc. Natl Acad. Sci. USA 103, 4675-4680.
8. Eriksen J. L., Dawson T. M., Dickson D. W., and, Petrucelli L., (2003) Caught in the act: alpha-synuclein is the culprit in Parkinson's disease. Neuron 40, 453-456.
9. Guillot T. S., and, Miller G. W., (2009) Protective actions of the vesicular monoamine transporter 2 (VMAT2) in monoaminergic neurons. Mol. Neurobiol. 39, 149-170.
10. Kawai H., Makino Y., Hirobe M., and, Ohta S., (1998) Novel endogenous 1,2,3,4-tetrahydro- isoquinoline derivatives: uptake by dopamine transporter and activity to induce parkinsonism. J. Neurochem. 70, 745-751.
11. Kawai H., Kotake Y., and, Ohta S., (2000a) Inhibition of dopamine receptors by endogenous amines: binding to striatal receptors and pharmacological effects on locomotor activity. Bioorg. Med. Chem. Lett. 10, 1669-1671.
12. Kawai H., Kotake Y., and, Ohta S., (2000b) Dopamine transporter and catechol-O-methyltrans- ferase activities are required for the toxicity of 1-(3',4'-dihydroxybenzyl)-1,2,3,4-tetrahydro- isoquinoline. Chem. Res. Toxicol. 13, 1294-1301.
13. Koharudin L. M. I., Liu H., Di Maio R., Kodali R. B., Graham S. H., and, Gronenborn A. M., (2010) Cyclopentenone prostaglandin-induced unfolding and aggregation of the Parkinson disease-associated UCH-L1. Proc. Natl Acad. Sci. USA 107, 6835-6840.
14. Kohno M., Ohta S., and, Hirobe M., (1986) Tetrahydroisoquinoline and 1-methyl-tetrahydroiso- quinoline as novel endogenous amines in rat brain. Biochem. Biophys. Res. Commun. 140, 448-454.
15. Kohta R., Kotake Y., Hosoya T., et al,. (2010) 1-Benzyl-1,2,3,4-tetrahydroisoquinoline binds with tubulin β, a substrate of parkin, and reduces its polyubiquitination. J. Neurochem. 114, 1291-1301.
16. Kotake Y., Tasaki Y., Makino Y., Ohta S., and, Hirobe M., (1995) 1-Benzyl-1,2,3,4-tetrahydro- isoquinoline as a parkinsonism-inducing agent-a novel endogenous amine in mouse brain and parkinsonian CSF. J. Neurochem. 65, 2633-2638.
17. Kotake Y., Yoshida M., Ogawa M., Tasaki Y., Hirobe M., and, Ohta S., (1996) Chronic admi- nistration of 1-benzyl-1,2,3,4-tetrahydroisoquinoline, an endogenous amine in the brain, induces parkinsonism in a primate. Neurosci. Lett. 217, 69-71.
18. Kumagai Y., Shinkai Y., Miura T., and, Cho A. K., (2012) The chemical biology of naphthoquinones and its environmental implications. Annu. Rev. Pharmacol. Toxicol. 52, 221-247.
19. Laemmli U. K., (1970) Cleavage of structural proteins during assembly of head of bacterio- phage-T4. Nature 227, 680-685.
20. Lau Y. S., Trobough K. L., Crampton J. M., and, Wilson J. A., (1990) Effects of probenecid on striatal dopamine depletion in acute and long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated mice. Gen. Pharmacol. 21, 181-187.
21. LaVoie M. J., Ostaszewski B. L., Weihofen A., Schlossmacher M. G., and, Selkoe D. J., (2005) Dopamine covalently modifies and functionally inactivates parkin. Nat. Med. 11, 1214-1221.
22. Leroy E., Boyer R., Auburger G., et al,. (1998) The ubiquitin pathway in Parkinson's disease. Nature 395, 451-452.
23. Liu Y. C., Fallon L., Lashuel H. A., Liu Z. H., and, Lansbury P. T., (2002) The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility. Cell 111, 209-218.
24. Maraganore D. M., Farrer M. J., Hardy J. A., Lincoln S. J., McDonnell S. K., and, Rocca W. A., (1999) Case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease. Neurology 53, 1858-1860.
25. Meray R. K., and, Lansbury P. T., (2007) Reversible monoubiquitination regulates the Parkin- son disease-associated ubiquitin hydrolase UCH-L1. J. Biol. Chem. 282, 10567-10575.
26. Meredith G. E., Baldo B. A., Andrezjewski M. E., and, Kelley A. E., (2008) The structural basis for mapping behavior onto the ventral striatum and its subdivisions. Brain Struct. Funct. 213, 17-27.
27. Miller G. W., Erickson J. D., Perez J. T., Penland S. N., Mash D. C., Rye D. B., and, Levey A. I., (1999) Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Exp. Neurol. 156, 138-148.
28. Miura T., Kakehashi H., Shinkai Y., Egara Y., Hirose R., Cho A. K., and, Kumagai Y., (2011a) GSH-mediated S-transarylation of a quinone glyceraldehyde-3-phosphate dehydrogenase conjugate. Chem. Res. Toxicol. 24, 1836-1844.
29. Miura T., Shinkai Y., Hirose R., Iwamoto N., Cho A. K., and, Kumagai Y., (2011b) Glyceraldehyde-3-phosphate dehydrogenase as a quinone reductase in the suppression of 1,2-naphthoquinone protein adduct formation. Free Radic. Biol. Med. 51, 2082-2089.
30. Morris G. M., Huey R., Lindstrom W., Sanner M. F., Belew R. K., Goodsell D. S., and, Olson A. J., (2009) Autodock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 16, 2785-2791.
31. Nishikawa K., Li H., Kawamura R., et al,. (2003) Alterations of structure and hydrolase acti- vity of Parkinsonism-associated human ubiquitin carboxyl-terminal hydrolase L1 variants. Biochem. Biophys. Res. Commun. 304, 176-183.
32. Ohta S., Kohno M., Makino Y., Tachikawa O., and, Hirobe M., (1987) Tetrahydroisoquinoline and 1-methyl-tetrahydroisoquinoline are present in the human brain-relation to Parkinson's disease. Biomed. Res. 8, 453-456.
33. Osaka H., Wang Y. L., Takada K., et al,. (2003) Ubiquitin carboxy-terminal hydrolase L1 binds to and stabilizes monoubiquitin in neuron. Hum. Mol. Genet. 12, 1945-1958.
34. Pettersen E. F., Goddard T. D., Huang C. C., Couch G. S., Greenblatt D. M., Meng E. C., and, Ferrin T. E., (2004) UCSF chimera: a visualization system for exploratory research and analysis. J. Comput. Chem. 25, 1605-1612.
35. Rudolph T. K., and, Freeman B. A., (2009) Transduction of redox signaling by electrophile-protein reactions. Sci. Signal. 2, re7.
36. Sanner M. F., (1999) Phyton: a programming language for software integration and development. J. Mol. Graph. Model. 17, 57-61.
37. Satoh J., and, Kuroda Y., (2001) A polymorphic variation of serine to tyrosine at codon 18 in the ubiquitin C-terminal hydrolase-L1 gene is associated with a reduced risk of sporadic Parkinson's disease in a Japanese population. J. Neurol. Sci. 189, 113-117.
38. Schlossmacher M. G., Frosch M. P., Gai W. P., et al,. (2002) Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies. Am. J. Pathol. 160, 1655-1667.
39. Segura-Aguilar J., Paris I., Muñoz P., Ferrari E., Zecca L., and, Zucca F. A., (2014) Protective and toxic roles of dopamine in Parkinson's disease. J. Neurochem. 10, 1111.
40. Setsuie R., and, Wada K., (2007) The functions of UCH-L1 and its relation to neurodegenerative diseases. Neurochem. Int. 51, 105-111.
41. Setsuie R., Wang Y. L., Mochizuki H., et al,. (2007) Dopaminergic neuronal loss in transgenic mice expressing the Parkinson's disease- associated UCH-L1 193M mutant. Neurochem. Int. 50, 119-129.
42. Tasaki Y., Makino Y., Ohta S., and, Hirobe M., (1991) 1-Methyl-1,2,3,4-tetrahydroisoquinoline, decreasing in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse, prevents parkinso- nism-like behavior abnormalities. J. Neurochem. 57, 1940-1943.
43. Toyama T., Shinkai Y., Kaji T., and, Kumagai Y., (2013) A convenient method to assess chemical modification of protein thiols by electrophilic metals. J. Toxicol. Sci. 38, 477-484.
44. Trott O., and, Olson A. J., (2010) Software news and update AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multi- threading. J. Comput. Chem. 31, 455-461.
45. Van Laar V. S., Mishizen A. J., Cascio M., and, Hastings T. G., (2009) Proteomic identification of dopamine-conjugated proteins from isolated rat brain mitochondria and SH-SY5Y cells. Neurobiol. Dis. 34, 487-500.
46. Wilkinson K. D., Lee K., Deshpande S., Duerksenhughes P., Boss J. M., and, Pohl J., (1989) The neuron-specific protein PGP-9.5 is a ubiquitin carboxyl-terminal hydrolase. Science 246, 670-673.
47. Wintermeyer P., Krüger R., Kuhn W., et al,. (2000) Mutation analysis and association studies of the UCHL1 gene in German Parkinson's disease patients. NeuroReport 11, 2079-2082.
48. Zhang J., Hattori N., Leroy E., Morris H. R., Kubo S. I., Kobayashi T., Wood N. W., Polymeropoulos M. H., and, Mizuno Y., (2000) Association between a polymorphism of ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) gene and sporadic Parkinson's disease. Parkinsonism Relat. Disord. 6, 195-197.